Impact of ICH Q9 and the application of Risk Management
|
|
- Rosamund Moody
- 6 years ago
- Views:
Transcription
1 Safeguarding public health Impact of ICH Q9 and the application of Risk Management An inspector s perspective on the impact on inspectional approaches and expectations Ian Thrussell Strategy and Development Team GMP Inspection Group I&S Division, MHRA, UK ian.thrussell@mhra.gsi.gov.uk
2 Content of the presentation Introductory background Words of caution Where are we coming from and where are we going? Issues from inspections Open forum for Q & As Slide 2
3 What do Regulators want from the so called 3 Qs Paradigm shift? Is the status quo any longer acceptable? How might the relationships between the pharmaceutical manufacturer and their suppliers support or inhibit whether and how these goals are met? What are the challenges? - How can we all work together to achieve these goals? Slide 3
4 Regulatory changes UK: Hampton Report Reducing administrative burdens: effective inspection and enforcement, March 2005 Executive summary: Risk assessment should be comprehensive, and should be the basis for all regulators enforcement programmes. Proper analysis of risk directs regulators efforts at areas where it is most needed, and should enable them to reduce the administrative burden of regulation, while maintaining or even improving regulatory outcomes. Slide 4
5 What is the big regulatory picture? EU regulators firmly believe that effective and robust processes should be - Designed from the outset to be optimally fit for purpose - Underpinned by the application of principles of Quality Risk Management - Operated under an effective quality system. EU Regulators are committed to safeguarding public health but are also committed to leaving sufficient flexibility to industry and to avoiding an increase in unnecessary requirements. EU Regulators are committed to fostering innovation! EU regulators firmly believe that they have been looking for RM in company inspections for many years! Slide 5
6 ICH Q9: Q9 which is unique as for industry and regulators : - Harmonised implementation within the EU (e.g. Q9 implementation group at the EMEA level for GMP related matters or working group of assessors) - Is optional but is not an open door to think that the EU legislation could also be optional - Already assessed by EU GMP inspectors with some good experiences and also lot of bad.. Slide 6
7 Inspecting industry risk cases involves a changing role of the GMP inspector: It is no longer just inspecting it is also: - to support companies to concentrate their ressources on real risks - to encourage companies to understand and use QRM - to encourage companies to make their risks transparent - to create an atmosphere of mutual confidence It is no longer just inspecting every 2 years inspectors will have to evaluate individually for each site the frequency and depth of inspections - not least based on company s overall QRM performance The inspector s job will become more scientific and related to real risks Slide 7 7
8 Sorts of industry risks Strategic risks: e.g. competitor advantage Operational risks: e.g. HSE (health, safety & environment) Financial risks: e.g. shareholder harm Compliance risks: e.g. patient harm Availability of goods / insufficient stock levels Slide 8
9 Reasons to apply QRM Support decisions to accept or not a risk Determine the minimum necessary effort to control a risk Determine cost-benefit of risk reduction measures Allocate ressources according to risk (staff, technical, financial) Prioritisation of risk reduction / control measures Show adequacy of risk reduction / control measures Review efficacy of risk reduction / control measures Survive an official GMP inspection [a misleading motivation ] Show compliance with Market Authorisation requirements (especially dossiers containing ICH Q8 QbD elements) Slide 9 9
10 Prospective uses lead question: what might go wrong? Examples Design of product development approaches Scope of qualifications, validations, tech transfers Evaluation of proposed changes - incl. intro of new products / processes / systems / people Focus of product quality reviews Scope of on-going stability programme Planning of self-inspections / third party audits Slide 10 10
11 Retrospective uses lead question: what has gone wrong? Examples reports of suspected quality defects OOS results at batch release testing undesigned deviations or OOL / OOT / OOE results, e.g. with respect to: - Manufacture - Environmental monitoring - Validation - Stability testing - Storage / transport Slide 11 11
12 Why do EU inspectors already look at an organisation s QMS and QRM programmes during inspections? Looking at how companies react when things go wrong and are under pressure is a major diagnostic indicator of the robustness of the scientific and organisational integrity of a company s operations - Do they investigate to improve knowledge or simply build arguments for release of product - Quality of investigations- appropriateness of depth of investigation - Reactive rather than proactive usage - Quality is everyone s responsibility Is this true when things go wrong? Slide 12
13 Importance of root cause investigations and risk management Slide 13
14 Management Responsibilities Senior management commitment Development and maintenance of the quality system Provide the leadership needed for the successful functioning of the quality system Adequate provision of resources Encourage internal communication on quality issues at all levels of the organization (QU, R&D, RA, manufacturing, etc.) Ensure assigned authorities and responsibilities support production, quality, and management activities Ensure that there is Informed decision-making processes with the participation of key components or the organization using product and process knowledge and risk management tools Slide 14
15 No use of QRM For release of a batch not meeting its specification [cf. EMA Reflection Paper on QP discretion] As a means not to comply with or to circumvent regulatory or GMP requirements As a means to hide risks As a means to hide insufficient risk control Slide 15 15
16 Debatable Examples Scope of testing of pesticides in herbal drugs to be used in homeopathic finished products TSE risk of animal origin starting materials to be used in vet products for non-food animals Control of transport conditions for finished products for which no particular conditions are specified Requirements for a clean area used only sporadically and only for incoming goods sampling of non-sterile APIs to be used in sterile finished products Slide 16 16
17 A few words about risk based C & Q Often the inspector is left wondering exactly why a company has done what it has done! Has the company really explained why it has qualified/validated what it has done? Does it know or is it simply the presenter? Is the company simply trying to waste the time of the inspector? Slide 17
18 Good risk assessment and summaries! Adds clarity! Aids communication! It tells a convincing story! Has the company a process map? - Can it demonstrate that it has covered what appear to be the key points? Is the output and outcome from the assessment actually implemented? Does the process actually perform better? What about the residual risks? Slide 18
19 What does MHRA Inspectors see as the greatest risks for processes seen in inspection? People: - Their lack of experience, knowledge & understanding Individually and at the corporate level Are companies learning organisations - Over confidence in process robustness - Human ingenuity to interfere in the best designed processes - Change control Process and Equipment: - Poor process design - Operational integrity of transfer technology processes Slide 19
20 Crown copyright 2010 The materials featured within this MHRA presentation are subject to Crown copyright protection. Any other copy or use of Crown copyright materials featured in this presentation, in any form or medium, is subject to prior approval of the MHRA which has Delegated Authority from Her Majesty's Stationery Office (HMSO) to administer Crown copyright for MHRA originated material. Applications should be in writing, clearly stating the proposed use/reuse of the information, and should be sent to the MHRA at the following address: Conference and Education Function, 16 th Floor, MHRA, 1 Nine Elms Lane, London SW8 5NQ. Fax or e- mail speakers@mhra.gsi.gov.uk. You may not sell or resell any information reproduced to any third party without prior agreement. The permission to reproduce Crown copyright protected material does not extend to any material in this pack which is subject to a separate licence or is the copyright of a third party. Authorisation to reproduce such material must be obtained from the copyright holders concerned. Slide 20
ICH Q10 Pharmaceutical Quality System
Safeguarding public health ICH Q10 Pharmaceutical Quality System An EU Regulator s Perspective Presentation overview Why does Q10 exist and what were the desired outcomes Content of the Q10 step 2 document
More informationATMP GMP requirements. Andrew Hopkins
Andrew Hopkins Scope GMP for ATMPs Points to consider Survey MHRA next steps Questions 2 GMP for ATMPs The usual process for GMP updates Problem statement submitted to IWG and PIC/S Reviewed and if accepted
More informationHealth Based Exposure Limits (HBEL) and Q&As
Health Based Exposure Limits (HBEL) and Q&As The EMA guideline (EMA/CHMP/ CVMP/ SWP/169430/2012) & EMA/CHMP/CVMP/SWP/463311/2016 Graeme McKilligan, UK, MHRA. Content Intent of HBEL Post Implementation
More informationChallenges of Implementation of ICH Q 8
Challenges of Implementation of ICH Q 8 A Regulatory Perspective Dr. Susanne Keitel BioKorea, Seoul, September 2007 Overview of the Presentation ICH Q 8: Background; EU Experience Design Space Associated
More informationImportance of ICH Guidance in Fulfilling Process Validation Requirements
Importance of ICH Guidance in Fulfilling Process Validation Requirements Presented by: Gamal Amer All rights reserved. Do not copy without permission. Principal 1 Premier Compliance Services, Inc. Process
More informationImplementing Quality Systems
Implementing Quality Systems CGMP By The Sea August 29, 2006 Chris Joneckis, Ph.D. Senior Advisor For CMC Issues Center For Biologics Evaluation And Research Add FDA Bar and Presentation Overview Driving
More informationMAH Responsibilities including the Management of CMOs. QP Forum Workshop. Robert Byrne and Eoin Duff Quality Assurance Alexion Pharmaceuticals
MAH Responsibilities including the Management of CMOs QP Forum 2017 - Workshop Robert Byrne and Eoin Duff Quality Assurance Alexion Pharmaceuticals 25 th April 2017 Alexion Pharmaceuticals in Ireland A
More informationInter-Association Task Force
Inter-Association Task Force Presentation to EMA Workshop Prevention of Drug Shortages Based on Quality and Manufacturing Issues 9 th October 2015 1 Topics for Today Background and history of task force
More informationMedical Devices cyber risks and threats
Medical Devices cyber risks and threats David Grainger Senior Medical Device Specialist MHRA The challenges of software medical device regulation. david.grainger@mhra.gov.uk Current framework 1998 In Vitro
More informationClaus Mortensen, Medicines Inspector. Danish Medicines Agency. Member of the EMEA PAT team
Claus Mortensen, Medicines Inspector Danish Medicines Agency Member of the EMEA PAT team EMEA progress and status what is needed to document scientific understanding in a PAT application EMEA PAT team
More informationOffice for Nuclear Regulation Strategy
Office for Nuclear Regulation Strategy 2015 to 2020 Office for Nuclear Regulation page 1 of 12 Office for Nuclear Regulation page 2 of 12 Office for Nuclear Regulation Strategy 2015 to 2020 Presented to
More informationICH Q8, 9 & 10 and the Impact on the QP
1 ICH Q8, 9 & 10 and the Impact on the QP Peter H. Gough David Begg Associates phg@david-begg-associates.com 2 A New Approach to Regulation Approach to the regulation of pharmaceuticals is undergoing a
More informationValue Paper. Are you PAT and QbD Ready? Get up to speed
Value Paper Are you PAT and QbD Ready? Get up to speed PAT and Quality-by-Design As PAT and Quality -by-design (QbD) become an integral part of the regulatory framework, automation group ABB argues more
More informationCDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals
CDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals Lawrence X. Yu, Ph.D. Director (acting) Office of Pharmaceutical Science Food and Drug Administration IFPAC
More informationEDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE : 20 YEARS OF EXPERIENCE March EDQM, Strasbourg, France ABSTRACTS
EDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE 1992-2012: 20 YEARS OF EXPERIENCE 22-23 March 2012 EDQM, Strasbourg, France ABSTRACTS PLENARY SESSION, 22 March 2012 ABSTRACT 1.3 The Evolution
More informationTHE USE OF A SAFETY CASE APPROACH TO SUPPORT DECISION MAKING IN DESIGN
THE USE OF A SAFETY CASE APPROACH TO SUPPORT DECISION MAKING IN DESIGN W.A.T. Alder and J. Perkins Binnie Black and Veatch, Redhill, UK In many of the high hazard industries the safety case and safety
More informationEU GMP Evolution or Revolution Scope and drivers for EU GMP changes. August Gordon Farquharson
EU GMP Evolution or Revolution Scope and drivers for EU GMP changes August 2015 Gordon Farquharson EU & PIC/S Harmonisation at IWG level now Slide 2 PharmOut 2015 EU & PIC/S Harmonisation (1) What does
More informationThe Medical Device Regulation: Transitioning between old and new
Association of British Healthcare Industries The Medical Device Regulation: Transitioning between old and new www.abhi.org.uk www.bdia.org.uk Introduction In May 2017, the new Medical Device Regulation
More informationImplementation of Directive 2010/63/EU: - the animal welfare perspective
Animal experimentation Implementation of Directive 2010/63/EU: - the animal welfare perspective Kirsty Reid Scientific Officer Research Animals Eurogroup for Animals @KirstyEG4A 21 st May 2015 312 th session
More informationCurrent Status and Challenges of Bilateral/Multilateral Meetings
Current Status and Challenges of Bilateral/Multilateral Meetings Junko Sato, PhD International Liaison Officer PMDA 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The views and
More informationChief Nuclear Inspector s Inspection of NNB GenCo Ltd. s Supply Chain Management Arrangements for the Hinkley Point C Project
Chief Nuclear Inspector s Inspection of NNB GenCo Ltd. s Supply Chain Management Arrangements for the Hinkley Point C Project 15 March 2018 Chief Nuclear Inspector s Inspection of NNB GenCo Ltd. s Supply
More informationWhat We Heard Report Inspection Modernization: The Case for Change Consultation from June 1 to July 31, 2012
What We Heard Report Inspection Modernization: The Case for Change Consultation from June 1 to July 31, 2012 What We Heard Report: The Case for Change 1 Report of What We Heard: The Case for Change Consultation
More informationQuality assurance in the supply chain for pharmaceuticals from the WHO perspective
1 Quality assurance in the supply chain for pharmaceuticals from the WHO perspective Dr Sabine Kopp Quality Assurance and Safety: Medicines Medicines Policy and Standards World Health Organization Presentation
More informationJustin McCarthy John Amoore, Paul Blackett, Fran Hegarty, Richard Scott. Regulations, Guidance and Standards
Justin McCarthy John Amoore, Paul Blackett, Fran Hegarty, Richard Scott Regulations, Guidance and Standards 1 What s it all about? Clarity regarding the difference between: Regulations Guidance Standards
More informationWG food contact materials
WG food contact materials Monday 30 January European Commission DG SANTE, Unit E2 Food Processing Technologies and Novel Foods Food Contact Materials This presentation does not present any official views
More informationTriennial Review of the Medicines and Healthcare Products Regulatory Agency. Call for Evidence
Triennial Review of the Medicines and Healthcare Products Regulatory Agency Call for Evidence Title: Triennial Review of the Medicines and Healthcare Products Regulatory Agency Call for Evidence Author:
More informationQuality Systems, Accreditation and the Food Sector
Presentation Outline Quality Systems, Accreditation and the Food Sector David Galsworthy Head of Quality Systems Team Central Science Laboratory York, UK My background The Quality Standards Accreditation
More informationTechnology Transfer as the Process of Pharmaceutical Quality System: Modelling Technology Transfer as a Process Strategy
Journal of Pharmacy and Pharmacology 5 (2017) 299-313 doi: 10.17265/2328-2150/2017.06.002 D DAVID PUBLISHING Technology Transfer as the Process of Pharmaceutical Quality System: Modelling Technology Transfer
More informationONR perspectives on design assessment and licensing of SMRs
ONR perspectives on design assessment and licensing of SMRs Nuclear Institute June 2016 Craig Reiersen Head of New Reactor Licensing Office for Nuclear Regulation Ana Gomez-Cobo New Reactor Safety Case
More informationTechnology Transfer Plays an Increasingly Important Role in Pharmaceutical Quality Systems
Technology Transfer Plays an Increasingly Important Role in Pharmaceutical Quality Systems A robust and secure manufactured product is the desired end result for pharmaceutical companies. Scale-up and
More informationPharmacovigilance Inspection Metrics Report
April 2013 - March 2014 Pharmacovigilance Inspection Metrics Report Introduction During the period 01 April 2013 to 31 March 2014, the Pharmacovigilance inspectorate conducted 56 inspections of Marketing
More informationQuality by Design and OINDP. Today s Presentation
Quality by Design and OINDP Setting the Stage John C Berridge IPAC-RS September 2008 Today s Presentation QbD definition Setting the stage from an ICH perspective Future Opportunities 2 QbD Definition
More informationGuidance for Industry
Guidance for Industry Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
More informationMedical Technology Association of NZ. Proposed European Union/New Zealand Free Trade Agreement. Submission to Ministry of Foreign Affairs & Trade
Medical Technology Association of NZ Proposed European Union/New Zealand Free Trade Agreement Submission to Ministry of Foreign Affairs & Trade February 2016 1 Introduction The Medical Technology Association
More informationClaudio Pincus, President, The Quantic Group R. Owen Richards, President, Quantic Regulatory Services Daniel Pincus, Consultant, The Quantic Group
FDA Compliance and Regulatory Symposium Understanding the FDA s Latest cgmp Guidances: Opportunities and Pitfalls Claudio Pincus, President, The Group R. Owen Richards, President, Regulatory Services Daniel
More informationSwissmedic, Swiss Agency for Therapeutic Products
PMDA International Forum, 8 February 2014 Swissmedic, Swiss Agency for Therapeutic Products Jürg H. Schnetzer, Executive Director Grüezi. Bonjour. Buongiorno. Allegra. 2 Overview Swissmedic Introduction
More informationICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective
14 th DIA Japan Annual Meeting 2017 November 12-14, 2017 Tokyo Big Sight Ariake ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective Yasuhiro Kishioka, Ph.D. Principal Reviewer Office
More informationProgressive Licensing and the Modernization of the Canadian Regulatory Framework
Progressive Licensing and the Modernization of the Canadian Regulatory Framework Workshop on Implementation of ICH Quality Guidelines Beijing, China 3-5 December, 2008 Mike Ward Health Canada 1 DISCLAIMER
More informationPHARMACEUTICAL QUALITY MANAGEMENT SYSTEM: A REVIEW
PHARMACEUTICAL QUALITY MANAGEMENT SYSTEM: A REVIEW Available online at www.ijdra.com REVIEW ARTICLE Sharma S*, Bodla R.B., Shweta S, Pathak D.P. Delhi Institute of Pharmaceutical Sciences and Research,
More informationONR Strategy 2015 to 2020
Title of publication ONR Strategy 2015 to 2020 Office for Nuclear Regulation Page 1 of 5 Introduction Nick Baldwin, Chair The Energy Act 2013 provided for the creation of ONR as an independent, statutory
More informationOffice for Nuclear Regulation
Office for Nuclear Regulation Redgrave Court Merton Road Bootle Merseyside L20 7HS www.hse.gov.uk/nuclear PROJECT ASSESSMENT REPORT Report Identifier: ONR-Policy-all-PAR-11-001 Revision: 2 Project: Implementation
More informationIGDRP Mission, Scope, How it works
IGDRP Mission, Scope, How it works IGDRP-EDQM Workshop Strasbourg, France 13 May 2016 Dr. Craig Simon Associate Director, Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada
More informationJustice Select Committee: Inquiry on EU Data Protection Framework Proposals
Justice Select Committee: Inquiry on EU Data Protection Framework Proposals Response by the Wellcome Trust KEY POINTS The Government must make the protection of research one of their priorities in negotiations
More informationQ8 and Q8 annex An industry Perspective
Workshop on Implementation of ICH Q8/Q9/Q10 and Other Quality Guidelines Beijing December 2008 Q8 and Q8 annex An industry Perspective Brian Withers, Abbott Laboratories, United Kingdom I attend this conference
More informationEDQM Conference. Quality of Medicines in a Globalised World: Dreams and Reality
EDQM Conference Quality of Medicines in a Globalised World: Dreams and Reality 14-15 October 2010 Prague, Czech Republic 2010 EDQM, Council of Europe, All rights reserved Dr Georges France Ms Suzette Kox
More information(Non-legislative acts) DECISIONS
4.12.2010 Official Journal of the European Union L 319/1 II (Non-legislative acts) DECISIONS COMMISSION DECISION of 9 November 2010 on modules for the procedures for assessment of conformity, suitability
More informationVENUE. 2 DAY WORKSHOP On FDA Penalties for Regulatory Non-Compliance in the Pharmaceuticals Industry in Review , JAN San Diego CA
WORLD COMPLIANCE SEMINARS SPEAKER:- BRIAN G. NADEL President of Brian G. Nadel, GMP Consulting, LLC. 2 DAY WORKSHOP On FDA Penalties for Regulatory Non-Compliance in the Pharmaceuticals Industry - 2017
More informationEnvironmental Protection Agency
Good Laboratory Management: Means compliance with the correct regulations for each individual study.. Environmental Protection Agency Established 1970 To enforce environmental protection standards Clean
More informationCultural Evolution Is the future in our own hands?
Cultural Evolution Is the future in our own hands? Dr Paul Litchfield - Chief Medical Officer, BT Group Laura Collins - Carer and East Belfast ICP member Colette Goldrick - NI Director, APBI Dr Anne Kilgallen
More informationRecast de la législation européenne et impact sur l organisation hospitalière
Recast de la législation européenne et impact sur l organisation hospitalière MEDICAL DEVICES IN BELGIUM. What s up? Brussels44Center 24.10.2017 Valérie Nys Need for changes? Regulatory system is highly
More informationAPIs global business developments
APIs global business developments Dr Gian Mario Baccalini EFCG Board Member, Chairman of EFCG Pharma Business Committee President & CEO, Euticals S.p.A., Italy EFCG Press Conference, 13th October 2015,
More informationCHECKLIST FOR DESIGNATING AUTHORITIES DESIGNATION OF NOTIFIED LABORATORY. 1. General Requirement Complies Comments
LAMPIRAN I PERATURAN MENTERI KOMUNIKASI DAN INFORMATIKA REPUBLIK INDONESIA NOMOR TAHUN TENTANG PETUNJUK PELAKSANAAN PENGAKUAN BALAI UJI NEGARA ASING CHECKLIST FOR DESIGNATING AUTHORITIES DESIGNATION OF
More informationKeeping Your House in order?
Keeping Your House in order? A view on Safety Reviews from UK Offshore experience Ian Wright Business Development Director, Upstream DNV Energy, Europe & North Africa March 2009 Introduction Safety Performance
More informationFeedback EMEA / Industry Discussion
Feedback EMEA / Industry Discussion Eli Lilly & Co Ltd Case Study: Use of In-Line Near-Infrared Spectroscopy to Monitor Segregation of a Pharmaceutical Powder Blend in a Tablet Press Martin Diller PhD,
More informationTable Of Content. Stichting Health Action International... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs...
Table Of Content... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs... 7 D08 - HAI Europe Newsletter (EN)... 7 D01 - HAI Europe leaflet (EN)... 7 D02 - Briefing Papers and statements
More informationPreparing for the new Regulations for healthcare providers
Preparing for the new Regulations for healthcare providers Cathal Brennan, Medical Device Assessor HPRA Information Day on Medical Devices 23 rd October 2014 Brussels, 26.9.2012 COM(2012) 542 final 2012/0266
More informationSUSTAINABLE GROWTH AGREEMENT STIRLING COUNCIL AND SCOTTISH ENVIRONMENT PROTECTION AGENCY
SUSTAINABLE GROWTH AGREEMENT STIRLING COUNCIL AND SCOTTISH ENVIRONMENT PROTECTION AGENCY 27 AUGUST 2018 Sustainable Growth Agreement Stirling Council and Scottish Environment Protection Agency 3 OUR JOINT
More informationERC/DEC/(01)07 EUROPEAN RADIOCOMMUNICATIONS COMMITTEE
EUROPEAN RADIOCOMMUNICATIONS COMMITTEE ERC Decision of 12 March 2001 on harmonised frequencies, technical characteristics and exemption from individual licensing of Short Range Devices used for Radio Local
More informationAgency Information Collection Activities; Proposed Collection; Comment Request; Good
This document is scheduled to be published in the Federal Register on 06/12/2014 and available online at http://federalregister.gov/a/2014-13787, and on FDsys.gov DEPARTMENT OF HEALTH AND HUMAN SERVICES
More informationPerspective of veterinary SMEs on challenges meeting the requirements for authorisation of vaccines in the EU
Perspective of veterinary SMEs on challenges meeting the requirements for authorisation of vaccines in the EU Dr Rhona Banks Veterinary Biologicals Consultant Objective Particular challenges faced by SMEs
More informationDoing, supporting and using public health research. The Public Health England strategy for research, development and innovation
Doing, supporting and using public health research The Public Health England strategy for research, development and innovation Draft - for consultation only About Public Health England Public Health England
More informationApplication for Assessment of a full quality assurance system regarding Measuring Instruments in accordance with MID
Application for Assessment of a full quality assurance system regarding Measuring Instruments in accordance with MID Company (applicant): hereby applies to RISE Research Institutes of Sweden AB, as Notified
More informationTHE LABORATORY ANIMAL BREEDERS ASSOCIATION OF GREAT BRITAIN
THE LABORATORY ANIMAL BREEDERS ASSOCIATION OF GREAT BRITAIN www.laba-uk.com Response from Laboratory Animal Breeders Association to House of Lords Inquiry into the Revision of the Directive on the Protection
More informationEXPLORATION DEVELOPMENT OPERATION CLOSURE
i ABOUT THE INFOGRAPHIC THE MINERAL DEVELOPMENT CYCLE This is an interactive infographic that highlights key findings regarding risks and opportunities for building public confidence through the mineral
More informationSafety recommendations for nuclear power source applications in outer space
United Nations General Assembly Distr.: General 14 November 2016 Original: English Committee on the Peaceful Uses of Outer Space Scientific and Technical Subcommittee Fifty-fourth session Vienna, 30 January-10
More information25 July 2017 Without prejudice [PROVISIONS IN RELATION TO TRADE IN GOODS ALREADY INCLUDED IN THE EU TEXT PROPOSAL FOR THE TRADE IN GOODS CHAPTER]
25 July 2017 Without prejudice This document is the European Union's (EU) proposal for legal text provisions on energy and raw materials in the EU-Indonesia FTA. It will be tabled for discussion with Indonesia.
More informationQuality Risk Management
Quality Risk Management Iron Chef Edition Keith D. Gibbs kage and sui generis Ninja Project Management My story shapes my perspective Bachelor of Science work in Earth Science with focus on Hydrogeology.
More informationB) Issues to be Prioritised within the Proposed Global Strategy and Plan of Action:
INTERGOVERNMENTAL WORKING GROUP ON PUBLIC HEALTH, INNOVATION AND INTELLECTUAL PROPERTY EGA Submission to Section 1 Draft Global Strategy and Plan of Action The European Generic Medicines Association is
More informationthe SPD company Dr Clive Simon, Principal, The SPD Company.
the SPD company With decades of local and international experience at the coalface, The SPD Company s specialists have built a solid repertoire of in-depth technical knowledge within the highly-regulated
More informationEU, USA and Japan (II) Reports from Regulators on Exchange Assignments
EU, USA and Japan (II) Reports from Regulators on Exchange Assignments Yoshikazu Hayashi MHLW/PMDA Liaison at EMA PMDA 24th Annual EuroMeeting 26-28 March 2012 Copenhagen, Denmark Disclaimer The views
More informationWHITE PAPER FACILITY FOCUS: Next Generation Aseptic Manufacturing: An Eye-Opening Peek into the Future. By: Hite Baker
WHITE PAPER FACILITY FOCUS: Next Generation Aseptic Manufacturing: An Eye-Opening Peek into the Future By: Hite Baker August 2017 Introduction This Facility Focus Survey Report explores how to design sterile
More informationThe UK Generic Design Assessment
The UK Generic Design Assessment Dr Diego Lisbona Deputy Delivery Lead Advanced Modular Reactors Nuclear Safety Inspector New Reactors Division Infrastructure Development Working Group (IDWG) workshop,
More informationOverview on Medicines Regulation: regulatory cooperation and harmonization in focus
Overview on Medicines Regulation: regulatory cooperation and harmonization in focus Dr Samvel Azatyan Manager, Medicines Regulatory Support Programme Quality Assurance and Safety: Medicines Essential Medicines
More informationMember of the European Commission responsible for Transport
Member of the European Commission responsible for Transport Quality Shipping Conference It gives me great pleasure to offer you a warm welcome on behalf of all of the organisers of today s event. Lisbon,
More informationQuality and GLP for Histology and Pathology of Drug Safety Studies
Quality and GLP for Histology and Pathology of Drug Safety Studies Roger Alison BVSc MRCVS DiplECVP Consultant Toxicological Pathologist What is Quality Histology? It depends upon the purpose - Answer
More informationKEY HIGHLIGHTS WORKSHOP 2019
KEY HIGHLIGHTS aenvironmental Monitoring afacility Design apractical Case Studies avisual Inspection aclean Room Behaviours aprocess Simulations arecent 483s, warning Letters and EU Observations WORKSHOP
More informationby: J.A.M. van Balken, EFMA, Belgium and Tore K. Jenssen, Norsk Hydro ASA, Norway
EFMA S PRODUCT STEWARDSHIP PROGRAM by: J.A.M. van Balken, EFMA, Belgium and Tore K. Jenssen, Norsk Hydro ASA, Norway Introduction Mr. Chairmen, Ladies and Gentlemen. I am very happy that the organizing
More informationMEDICAL DEVICES : Guidance document
EUROPEAN COMMISSION DG ENTERPRISE Directorate G Unit 4 - Pressure Equipment, Medical Devices, Metrology MEDICAL DEVICES : Guidance document MEDDEV 2.10-2 Rev. 1 April 2001 (NOTE: For attachment 1 to 4
More informationFreedom of Information Act 2000 (FOIA) Decision notice
Freedom of Information Act 2000 (FOIA) Decision notice Date: 21 June 2017 Public Authority: Address: NHS Guildford and Waverley Clinical Commissioning Group 3 rd Floor Dominion House Woodbridge Road Guildford
More informationMachine safety: why sticking to standards is a step in the right direction
(Courtesy of Process Engineering, December 2016) (http://adserver.adtech.de/?adlink/1309/5932688/0/225/adid=16245674;bnid=2;itime=722418487;) Home (/) Safety/HSE (/category/1018/safety-hse) Machine safety:
More informationGeneral Manager Assurance and Risk Management in Oakton;
AHSPO Conference C f Is it a Legal Catch Probity & Management Management 23 O October t b 2009 My Background Chartered Accountant and Certified Internal Auditor; General Manager Assurance and Risk Management
More informationUSTR NEWS UNITED STATES TRADE REPRESENTATIVE. Washington, D.C UNITED STATES MEXICO TRADE FACT SHEET
USTR NEWS UNITED STATES TRADE REPRESENTATIVE www.ustr.gov Washington, D.C. 20508 202-395-3230 FOR IMMEDIATE RELEASE August 27, 2018 Contact: USTR Public & Media Affairs media@ustr.eop.gov UNITED STATES
More informationpeace of mind For from development to commercial supply
For peace of mind from development to commercial supply aesica-pharma.com weshouldtalk@aesica-pharma.com @aesica CorporateBroEng_v2 0814 @ Aesica 2014 Your full service CDMO Our vision: To be the number
More informationECA. Avoiding Failures & Rejects in Parenteral Manufacturing September 2014, Copenhagen, Denmark. and beyond.
ECA ACADEMY Speakers Martin Dearden UCB Derek Duncan Lighthouse Dr Helmut Gaus Boehringer Ingelheim Al Goodwin Amgen Uli Kuchenbrod Vetter Pharma-Fertigung *New Programme* Image: Seidenader Dr Stephen
More informationFuture of Pharmaceutical Quality and the Path to Get There
Future of Pharmaceutical Quality and the Path to Get There Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research INTERPHEX 2018, April 18, 2018,
More informationAustralian Communications and Media Authority (ACMA)
Australian Communications and Media Authority (ACMA) Compliance & Field Operations Section Operations, Services and Technology Branch Overview Who is the ACMA How are Radiocommunications regulated LIPD
More informationTechnical Documentation - Key pit falls
Technical Documentation - Key pit falls Itoro Udofia, PhD Global Head, Orthopaedic & Dental Devices Presented by Ibim Tariah Ph.D Technical Director Healthcare Solutions September 2012 TFD00101ENUK Overview
More informationINSPIRING TECHNICAL EXCELLENCE
INSPIRING TECHNICAL EXCELLENCE A new world-class training facility for Oman Introducing TPO Takatuf Petrofac Oman (TPO) is a new joint venture founded by Takatuf, the Human Capital solutions provider,
More informationICH Q7 - API. Presented by Ashley Isbel 4 July, 2016
ICH Q7 - API Presented by Ashley Isbel 4 July, 2016 ICH Q7 ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (November 2000) Adopted or referenced by: PIC/S in 2007 - Guide
More informationSubmission to the Productivity Commission inquiry into Intellectual Property Arrangements
Submission to the Productivity Commission inquiry into Intellectual Property Arrangements DECEMBER 2015 Business Council of Australia December 2015 1 Contents About this submission 2 Key recommendations
More informationETSI EN V1.3.1 ( )
EN 300 422-2 V1.3.1 (2011-08) Harmonized European Standard Electromagnetic compatibility and Radio spectrum Matters (ERM); Wireless microphones in the 25 MHz to 3 GHz frequency range; Part 2: Harmonized
More information75 Steps to Start-Up Success
75 Steps to Start-Up Success Hundreds of thousands of small businesses start up each year throughout the world - and a similar number cease trading every year too! A lot of people come across ideas, due
More informationHong Kong Personal Data Protection Regulatory Framework From Compliance to Accountability
Legal Week s Corporate Counsel Forum 2016 Renaissance Harbour View Hotel 23 June 2016 Hong Kong Personal Data Protection Regulatory Framework From Compliance to Accountability Stephen Kai-yi Wong Privacy
More informationACV-Transcom Visserij:
ACV-Transport en Communicatie Register No: 22039112812-17 ACV-Transcom Visserij: Opinion on the 2009 Fisheries Green Paper. In April 2009 the European Commission published its Green Paper on a reform of
More informationNew concepts are emerging frequently in various fields such as: microprocessor sensors,
EMERGENCY SHUT DOWN SYSTEMS IN ONSHORE AND OFFSHORE PROCESS OPERATIONS J PEARSON, PRINCIPAL SPECIALIST INSPECTOR HEALTH & SAFETY EXECUTIVE LIVERPOOL SYNOPSIS This paper describes some of the latest developments
More informationWHO Regulatory Systems Strengthening Program
WHO Regulatory Systems Strengthening Program MVP RHT RSS CRS www.who.int Minimal capacity met Eligibility for vaccine PQ WHO listed NRAs WHO NRA 5 step capacity building Development of NRA benchmarking
More informationConvergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA
EUnetHTA European network for Health Technology Assessment Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA University of Tokyo, October 24,
More informationQuality by Design, Clinical Relevance & Lifecycle Considerations
Quality by Design, Clinical Relevance & Lifecycle Considerations Robert Iser Acting Director Office of Process & Facilities / OPQ / CDER IFPAC 2016 1 FDA Quality Related Guidance and Initiatives Initiatives
More informationOffice for Nuclear Regulation
Summary of Lessons Learnt during Generic Design Assessment (2007 2013) ONR-GDA-SR-13-001 Revision 0 September 2013 1 INTRODUCTION 1 The purpose of this document is to provide a summary of the key lessons
More informationLeader in Pharmaceutical Films
TSX-V: IGX OTCQX: IGXT Leader in Pharmaceutical Films Your Specialist in Contract Development & Manufacturing WE MAKE APPROVED DRUGS BETTER Our Mission We make approved drugs better, with next generation
More information